Fresenius SE (FRE) Fair Value & Analysis
Healthcare · DE · Market cap €23.5B
Fair value as of: Aug 13, 2026
From 25 valuation models · updated today
Share price +16.2% over the past month.
A solid business, but screening 33% overvalued on our models.
What matters now
- Solid but not exceptional quality (57/100) and above fair value, neither a clear bargain nor a standout compounder.
- Our model range runs from €27.44 (bear) to €48.50 (bull), base €32.15. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 57/100 (solid quality) with high evidence: the data supports the verdict.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range €18.41 – €50.71 · fair‑value band €27.44 – €48.50 · the €47.66 price screens above the €32.15 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Fresenius SE (FRE) currently trades at €47.66, while our model-based Fair Value estimate is €32.15, implying the stock looks roughly 32.5% overvalued today. The Quality Score stands at 57/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Fresenius SE generated revenue of €23.0B at a net margin of 6.4%. Revenue grew 2.0% year over year. It earns a return on equity of 7.8%. Net debt stands at €10.3B. Fundamentals as of Aug 13, 2026
Our scenario range runs from €27.44 (bear case) to €48.50 (bull case); at €47.66, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 8% below its 52-week high and 33% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -14% fair-value upside, at -33%, FRE screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 25 models by family
Widest divergence: Growth Earnings (€39.20) versus Dividend Discount (€16.16). Highest evidence: Growth DCF (80).
Notify me when FRE reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 55 · Market factors (momentum, volatility) 59
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa. It operates through Fresenius Kabi and Fresenius Helios segments.
Full company description
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa. It operates through Fresenius Kabi and Fresenius Helios segments. The Fresenius Kabi segment offers products for therapy and care of critically and chronically ill patients, including biopharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs, and IV fluids. It also provides biosimilar drugs; enteral and parenteral nutrition products; and medical technologies that include disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment operates hospitals, medical care centers, occupational health centers, prevention centers, and outpatient health centers, as well as provision of medical diagnostics. The company has a strategic collaboration with SAP SE and Avelios Medical GmbH for the development of a cloud-native, modular hospital information system that enables digitalization of clinical and administrative processes with AI integration. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is based in Bad Homburg vor der Höhe, Germany.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Fresenius SE reported revenue of €22.9B in FY2025 versus €37.1B in FY2021, a compound −11.4%/yr. Reported net income was €1.3B in FY2025, compounding −8.7%/yr from FY2021.
of which total revenue −1.8 pp · buybacks/dilution −0.3 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
FRE screens 33% overvalued. Compare with HCA Healthcare, Inc →
Recent news
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.
- Are Investors Undervaluing Fresenius SE & Co. (FSNUY) Right Now?
- Fresenius SE & Co KGaA (FSNUY) (Q2 2026) Earnings Call Highlights: Raises Full-Year EPS ...
- Fresenius Announces FDA Approval of Rituximab Biosimilar for the U.S. Market
- Fresenius Announces FDA and EMA Acceptance for Review of Vedolizumab Biosimilar Candidate
Peer Group
Medical Care Facilities · 265 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $414.59 | $547.67 | +32% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.67 SGD | 1.44 SGD | -46% |
| Tenet Healthcare Corporation THC | $266.79 | $330.25 | +24% |
| Rede D'Or São Luiz S.A RDOR3 | R$33.97 | R$47.31 | +39% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,565 | ₹2,955 | -65% |
| Aier Eye Hospital Group 300015 | ¥8.87 | ¥7.67 | -14% |
| Max Healthcare Institute Limited MAXHEALTH | ₹1,008 | ₹284.87 | -72% |
| Bangkok Dusit Medical Services Public Company BDMS | 19.70 THB | 18.57 THB | -6% |
| Fortis Healthcare Limited FORTIS | ₹906.15 | ₹300.29 | -67% |
Compare Fresenius SE with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Fresenius SE (FRE) overvalued or undervalued?
What is the fair value of FRE?
What is the quality score of FRE?
What is the revenue of Fresenius SE (FRE)?
What is the net profit margin of FRE?
Does Fresenius SE pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Fresenius SE and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.